CA2558029A1 - Ion binding polymers and uses thereof - Google Patents

Ion binding polymers and uses thereof Download PDF

Info

Publication number
CA2558029A1
CA2558029A1 CA002558029A CA2558029A CA2558029A1 CA 2558029 A1 CA2558029 A1 CA 2558029A1 CA 002558029 A CA002558029 A CA 002558029A CA 2558029 A CA2558029 A CA 2558029A CA 2558029 A1 CA2558029 A1 CA 2558029A1
Authority
CA
Canada
Prior art keywords
polymer
potassium
shell
binding
binding polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002558029A
Other languages
French (fr)
Other versions
CA2558029C (en
Inventor
Dominique Charmot
Han Ting Chang
Gerrit Klaerner
Michael James Cope
Mingjun Liu
Futian Liu
Tony Kwok-Kong Mong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor Pharma Technology AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35054544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2558029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Application filed by Individual filed Critical Individual
Priority to CA2806465A priority Critical patent/CA2806465C/en
Publication of CA2558029A1 publication Critical patent/CA2558029A1/en
Application granted granted Critical
Publication of CA2558029C publication Critical patent/CA2558029C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Claims (58)

1. A method of removing potassium from an animal subject need thereof comprising administering to said animal subject in an effective amount of a potassium-binding polymer, said polymer being capable of binding and removing from a gastrointestinal tract of said animal subject an average of about 1.5 mmol of potassium per gm of said polymer.
2. A method of removing potassium from an animal subject in need thereof comprising administering to said animal subject an effective amount of a potassium-binding polymer, said polymer having an in vitro potassium binding capacity of greater than about 5 mmol/gm of said polymer at a pH of greater than about 5.5.
3. A method of removing potassium from an animal subject in need thereof comprising administering to said animal subject an effective amount of a potassium-binding polymer, said polymer having an average in vivo potassium binding capacity of at least about 1.5 mmol/gm of said polymer.
4. A method of removing potassium from an animal subject in need thereof comprising administering to said animal subject an effective amount of a core-shell composition comprising a potassium-binding polymer and a shell, said shell being physically and/or chemically attached to said potassium-binding polymer.
5. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer is in a Ca2+-form, a H+-form, a NH4+-form, a Na+-form, or a combination thereof.
6. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer comprises a non metallic positively charged counter-ion.
7. The method of claim 6 wherein said non metallic positively charged counter-ion is at least one of an ion selected from alkylammonium, hydroxyalkylammonium, choline, taurine, carnitine, guanidine, creatine, adenine, and aminoacids or derivatives thereof.
8. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer comprises at least one polymer selected from an optionally crosslinked carboxylic polymer, an optionally crosslinked sulfonic polymer, an optionally crosslinked sulfamic polymer, an optionally crosslinked phosphoric polymer, and an anhydride thereof.
9. The method of claim 4 wherein said potassium-binding polymer is a polystyrene sulfonate.
10. The method of claim 8 wherein said potassium-binding polymer comprises a pK a-decreasing group attached to an acid group of said polymer.
11. The method of claim 10 wherein said pK a-decreasing group is an electron-withdrawing group.
12. The method of claim 11 wherein said electron-withdrawing group is a halide or an OR
group, wherein R is H or alkyl.
13. The method of claim 12 wherein said halide atom is fluoride, chloride, or bromide.
14. The method of claim 8 wherein said potassium binding polymer comprises a poly-fluoroacrylic acid polymer, a poly-difluoromaleic acid polymer, or a combination thereof.
15. The method of claim 14 wherein said potassium binding polymer comprises 2-fluoroacrylic acid crosslinked with divinylbenzene, ethylene bisacrylamide, N,N'-bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N'-methylenebisacrylamide, or a combination thereof.
16. The method of claim 15 wherein said potassium binding polymer comprises crosslinked 2-fluoroacrylic polymer or co-polymer, said polymer or co-polymer obtained by polymerization of an alkylester of 2-fluoroacrylic acid with divinylbenzene and followed by ester hydrolysis.
17. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer is at least one polymer selected from an optionally crosslinked 2-fluroacrylate polymer, an optionally crosslinked vinyl sulfonic acid polymer, and an optionally crosslinked vinyl phosphoric acid polymer.
18. The method of claim 4 wherein said potassium binding polymer comprises at least one polymer selected from an optionally crosslinked carboxylic, phosphoric, or sulfonic acid, or combination thereof and said shell comprises a positively charged polymer with low permeability to multivalent cations.
19. The method of claim 4 wherein said potassium binding polymer comprises an optionally crosslinked 2-fluoroacrylic and acrylic acid copolymer and said shell comprises a positively charged polymer with low permeability to multivalent cations.
20. The method of claim 18 wherein said shell comprises copolymers, at least one repeat unit of said copolymer being a vinylamine, ethyleneimine, propyleneimine, allylamine, methallylamine, vinylpyridine, alkyaminoalkyl(meth)acrylate, alkyaminoalkyl(meth)acrylamide, aminomethylstyrene, chitosan, or adduct of aliphatic or aromatic amine with at least one electrophile selected from an epichlorhydrine, an alkylhalide, and an epoxide, wherein the amine is optionally a quarternized form.
21. The method of claim 4 wherein said shell comprises an enteric coating, said coating being capable of disintegrating in a colon.
22. The method of claim 21 wherein said shell further comprises a non-enteric coating.
23. The method of claim 4 wherein said shell inhibits a binding of multi-valent cations to said potassium-binding polymer.
24. The method of claim 4 wherein said shell is coated on said potassium-binding polymer by a fluidized bed coating process
25. The method of claim 4 wherein said shell is positively charged.
26. The method of claim 4 wherein said shell enhances the oral palatability of said potassium-binding polymer.
27. The method of claim 4 wherein said shell comprises a polyethyleneimine polymer.
28. The method of claim 4 wherein said shell inhibits binding of a competing ion to said potassium-binding polymer.
29. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer preferentially binds a potassium ion over a competing ion, said competing ion being a sodium ion, a calcium ion, a magnesium ion, or a combination thereof.
30. The method of claim 1, 2, 3, or 4 wherein said animal subject is suffering from hyperkalemia.
31. The method of claim 1, 2, 3, or 4 wherein said potassium binding polymer is co-administered with a drug that promotes potassium retention.
32. The method of claim 1, 2, 3, or 4 wherein said composition is co-administered with an ACE inhibitor, an ARB, a potassium sparing diuretic, or any combination thereof.
33. The method of claim 1, 2, 3, or 4 wherein said potassium-binding polymer is combined with at least one pharmaceutically acceptable excipient to form a pharmaceutical formulation.
34. The method of claim 33 wherein said pharmaceutical formulation is an oral or rectal formulation.
35. The method of claim 34 wherein said oral formulation is a liquid formulation or a chewable tablet formulation.
36. A pharmaceutical formulation comprising a potassium-binding polymer and a pharmaceutically acceptable excipient, wherein said potassium-binding polymer comprises a crosslinked carboxylic polymer or an anhydride thereof with a pK a-decreasing group.
37. The pharmaceutical formulation of claim 36 wherein said potassium binding polymer comprises a crosslinked poly-fluoroacrylic acid polymer, a crosslinked poly-difluoromaleic acid polymer, or a combination thereof.
38. The pharmaceutical formulation of claim 37 wherein said potassium binding polymer comprises 2-fluoroacrylic acid crosslinked with divinylbenzene, ethylene bisacrylamide, or a combination thereof.
39. A pharmaceutical formulation comprising a potassium-binding polymer and a pharmaceutically acceptable excipient, wherein said potassium-binding polymer comprises an optionally crosslinked .alpha.-fluroacrylate polymer, an optionally crosslinked vinyl sulfonic acid polymer, an optionally crosslinked vinyl phosphonic acid polymer, or a combination thereof.
40. A method of treating a disease comprising administering to an animal subject in need thereof an effective amount of a pharmaceutical composition of claim 36.
41. A method of determining a permeability of said shell of claim 4 to an ion comprising:
(a) attaching a composite membrane to a tube containing a donor solution, said composite membrane comprising said shell and a cellulose membrane and said donor solution comprising said ion;
(b) immersing said tube in an acceptor solution, said acceptor solution comprising said ion;
(c) sampling and analyzing said acceptor solution for said ion;
(d) determining a change in concentration of said ion in said acceptor solution;
said change in concentration being indicative of said permeability of said polymer membrane to said ion.
42. The method of claim 1, 2, 3 or 4 wherein less than 1% of said potassium-binding polymer can be absorbed from a gastrointestinal tract
43. A pharmaceutical compositon comprising a potassium-binding polymer and a pharmaceutically acceptable excipient, wherein said potassium-binding polymer comprises a a fluoroacrylate polymer crosslinked with divinyl benzene.
44. A method of treating a disease comprising administering to an animal subject in need thereof an effective amount of a pharmaceutical composition of claim 43.
45. A core-shell composition comprising a core and a shell, said core comprising a potassium binding polymer selected from polystyrene sulfonate or a fluoroacrylate polymer crosslinked with divinyl benzene and said shell comprising Eudragit RL 100, Eudragit RS
100, a combination thereof, benzylated polyethyleneimine, or N-dodecyl polyethyleneimine.
46. The composition of claim 45 wherein said shell comprises a mixture of Eudragit RL
100 and Eudragit RS 100 in a ratio of about 50: about 50.
47. The composition of claim 45 wherein said shell comprises benzylated polyethyleneimine with a degree of benzylation being about 20% to about 99% of nitrogen mole content.
48. The composition of claim 45 wherein said shell comprises N-dodecyl polyethyleneimine with a degree of dodecyl alkylation being about 20% to about 99% of nitrogen mole content.
49. The composition of claim 45 wherein said core-shell composition is synthesized by a Wurster fluid bed coating process or a controlled coating precipitation process.
50. The composition of claim 49 wherein said controlled coating precipitation process is a solvent coacervation process, a pH triggered precipitation process, or temperature triggered precipitation process.
51. A method of treating a disease comprising administering to an animal subject in need thereof an effective amount of a core-shell composition of claim 45.
52. A method of removing potassium from an animal subject comprising administering to said animal subject in need thereof an effective amount of a pharmaceutical composition comprising a potassium-binding polymer and a pharmaceutically acceptable excipient, wherein said potassium-binding polymer comprises a a fluoroacrylate polymer crosslinked with divinyl benzene.
53. A method of removing potassium from an animal subject in need thereof comprising administering to said animal subject an effective amount of a core-shell composition comprising a core and a shell, said core comprising a potassium binding polymer selected from polystyrene sulfonate or a fluoroacrylate polymer crosslinked with divinyl benzene and said shell comprising Eudragit RL 100, Eudragit RS 100, a combination thereof, or benzylated polyethyleneimine.
54. The method of claim 52 or 53 wherein said animal subject is suffering from hyperkalemia.
55. The method of claim 52 or 53 wherein said composition is co-administered with a drug that promotes potassium retention.
56. The method of claim 52 or 53 wherein said composition is co-administered with an ACE inhibitor, an ARB, a potassium sparing diuretic, or any combination thereof.
57. A method of synthesis of .alpha.-fluoroacrylate polymer comprising suspension polymerization of a .alpha.-fluoroacrylate monomerin the presence of a low water soluble free radical initiator and a water soluble salt.
58. The method of claim 57 wherein said low water soluble free radical initiator is lauryl peroxide and said water soluble salt is sodium chloride.
CA2558029A 2004-03-30 2005-03-30 Ion binding polymers and uses thereof Active CA2558029C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2806465A CA2806465C (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/813,872 2004-03-30
US10/814,749 2004-03-30
US10/814,527 2004-03-30
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/965,274 2004-10-13
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
PCT/US2005/010978 WO2005097081A1 (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2806465A Division CA2806465C (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof

Publications (2)

Publication Number Publication Date
CA2558029A1 true CA2558029A1 (en) 2005-10-20
CA2558029C CA2558029C (en) 2013-05-07

Family

ID=35054544

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2558029A Active CA2558029C (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof
CA2557848A Expired - Fee Related CA2557848C (en) 2004-03-30 2005-03-30 Ion binding compositions
CA2557999A Expired - Fee Related CA2557999C (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2557848A Expired - Fee Related CA2557848C (en) 2004-03-30 2005-03-30 Ion binding compositions
CA2557999A Expired - Fee Related CA2557999C (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances

Country Status (12)

Country Link
US (14) US7776319B2 (en)
EP (3) EP1732524B1 (en)
JP (3) JP4964122B2 (en)
KR (3) KR101228233B1 (en)
AU (3) AU2005231424B2 (en)
BR (3) BRPI0509331B8 (en)
CA (3) CA2558029C (en)
DE (1) DE112005000730B4 (en)
GB (3) GB2430367B (en)
MX (1) MXPA06011270A (en)
PL (1) PL1732523T3 (en)
WO (3) WO2005097072A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
AU2004266050B2 (en) 2003-08-26 2009-06-18 Takeda Pharmaceutical Company Limited Pharmaceutical formulation comprising lanthanum compounds
CA2558029C (en) * 2004-03-30 2013-05-07 Ilypsa, Inc. Ion binding polymers and uses thereof
KR20130086262A (en) * 2004-03-30 2013-07-31 리립사, 인크. Ion binding polymers and uses thereof
AU2006294455B2 (en) * 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
WO2007041569A1 (en) * 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
CN100398112C (en) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 Medicine for treating hyperphosphatemia and its preparing method
RS52706B (en) * 2006-10-06 2013-08-30 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
US8779119B2 (en) 2006-12-26 2014-07-15 Jnc Corporation Metal salt of crosslinked cellulose derivative
US20100324280A1 (en) * 2006-12-26 2010-12-23 Otsuka Pharmaceutical Factory, Inc. Sodium absorption inhibitor, potassium absorption inhibitor, phosphorus absorption inhibitor and preventive agent, therapeutic agent and food containing the same
MX2009011898A (en) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Compositions and methods for treating disorders associated with salt or fluid retention.
US20110123604A1 (en) * 2007-08-29 2011-05-26 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
JP5294681B2 (en) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 Substrate processing apparatus and substrate transport method
AU2013204877B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
DE112009002063T5 (en) * 2008-08-22 2012-01-12 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use for treating hyperkalemia
US20120107381A1 (en) * 2009-05-13 2012-05-03 Relypsa, Inc. Powder formulations of potassium-binding active agents
ES2670580T3 (en) 2010-03-20 2018-05-31 Relypsa, Inc. Continuous procedure to prepare polyfluoroacrylate particles
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
CN108969535A (en) 2011-02-11 2018-12-11 Zs制药公司 For treating the micro porous zirconium silicate of potassemia
CN108276277A (en) 2011-06-27 2018-07-13 瑞立普萨公司 The fluorination of Polyacrylate and its derivatives
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
JP2015529640A (en) * 2012-07-11 2015-10-08 ズィーエス・ファーマ，インコーポレーテッド Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and an improved calcium-containing composition for the treatment of hyperkalemia
US20150196585A1 (en) * 2012-07-19 2015-07-16 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
US9982940B2 (en) 2012-08-09 2018-05-29 Patheon Austria Gmbh & Co Kg Process for drying polymeric materials
JP6475624B2 (en) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド Potassium binding agents for the treatment of hypertension and hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
MX360684B (en) 2012-10-22 2018-11-13 Zs Pharma Inc Microporous zirconium silicate for treating hyperkalemia.
LT3003327T (en) 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
WO2015087985A1 (en) * 2013-12-11 2015-06-18 株式会社資生堂 Marker for early diagnosis of kidney failure
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (en) * 2014-09-30 2019-02-13 積水化成品工業株式会社 Hollow resin particles and method for producing the same
EP3229816B1 (en) 2014-12-10 2020-02-05 Tricida Inc. Proton-binding polymers for oral administration
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (en) 2015-12-23 2017-06-23 Rjw Pharma Llc PROCEDURE FOR THE SYNTHESIS OF PATIROMER
BR112018072714A2 (en) 2016-05-06 2019-02-19 Tricida, Inc. hcl binding compositions for and method of treating acid-base disorders
JP2018125951A (en) * 2017-01-31 2018-08-09 日本電産株式会社 Motor and air blowing device with the same
EP3703706A4 (en) 2017-11-03 2022-04-27 Tricida Inc. Compositions for and method of treating acid-base disorders
JP7365631B2 (en) * 2019-09-02 2023-10-20 国立大学法人福井大学 Core-shell type polymer fine particles having phosphonic acid or phosphonic acid ester structure, particle dispersion, molded body, and method for producing the fine particles
CN113244339B (en) * 2021-06-04 2021-09-24 南京厚生药业有限公司 Cholestyramine powder for hyperlipidemia and preparation method thereof
EP4251171A1 (en) * 2021-11-17 2023-10-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
WO2024035944A1 (en) * 2022-08-12 2024-02-15 University Of Kansas Extraction of critical minerals using polyanions

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) * 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (en) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
SE8003805L (en) 1980-05-21 1981-11-22 Haessle Ab A PHARMACEUTICAL PREPARATION WITH IMPROVED EMISSION PROPERTY
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (en) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING PEARL POLYMERISATS OF UNIFORM PARTICLE SIZE
DE3149136A1 (en) * 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart DEVICE FOR REGULATING THE FUEL-AIR RATIO IN INTERNAL COMBUSTION ENGINES
JPS6090243A (en) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Small spherical crosslinked monoallylamine polymer and its preparation
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
KR920006865B1 (en) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 Method and apparatus for coating particles or liquid droplets
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (en) 1986-06-16 1988-02-16 Prodotti Formenti Srl PHARMACEUTICAL COMPOSITIONS WITH SEQUESTRANT ACTIVITY OF BILE ACIDS CONTAINING COLESTYRAMINE AS THE ACTIVE INGREDIENT, AND PROCEDURE TO PREPARE THEM
JPS63218713A (en) * 1987-02-17 1988-09-12 Daikin Ind Ltd Alpha-fluoroacrylic acid polymer and use thereof
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (en) * 1988-06-30 1991-09-27 Cortial NOVEL EXTENDED RELEASE PHARMACEUTICAL FORM BASED ON AN ACTIVE RESIN-PRINCIPLE COMPLEX
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (en) 1989-09-01 1991-03-07 Bayer Ag METHOD FOR PRODUCING (ALPHA) -FLUOROACRYLIC ACID DERIVATIVES
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
EP0464299B1 (en) * 1990-07-04 1995-01-11 Marcin Krotkiewski Antihypertensive preparation
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
ES2080549T3 (en) * 1992-03-28 1996-02-01 Hoechst Ag MEDICINES BASED ON POLYHYDROXYMETHYLENE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND USE.
AU672824B2 (en) 1992-08-20 1996-10-17 E.I. Du Pont De Nemours And Company Crosslinked polymeric ammonium salts
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH09506342A (en) 1993-11-25 1997-06-24 サルテルナテ・ベー・ブイ Particles that bind monovalent cations, and uses and methods of the particles for trapping and removing sodium and / or potassium ions
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (en) 1996-06-11 2007-02-21 株式会社大塚製薬工場 Guanidino compound reducing agent and moisture and potassium ion adsorbent
AU3508097A (en) 1996-06-26 1998-01-14 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
JP2001508762A (en) * 1996-06-27 2001-07-03 ジー．ディー．サール アンド カンパニー Particles consisting of an amphiphilic copolymer having a cross-linked outer shell region and inner core region, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (en) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc Life prolongation ratio improver for nephritis patient
HUP0100469A2 (en) 1997-12-19 2001-08-28 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
EP1126880A2 (en) 1998-11-06 2001-08-29 G.D. SEARLE & CO. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CA2355829A1 (en) * 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US6558665B1 (en) 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20030027789A1 (en) 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (en) 2000-08-07 2003-03-07 Solvay PROCESS FOR THE SYNTHESIS OF FLUOROORGANIC COMPOUNDS
JP2004517066A (en) 2000-11-20 2004-06-10 ダウ グローバル テクノロジーズ インコーポレイティド In vivo use of water-absorbable polymers
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
JP2004149525A (en) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd Potassium ion adsorbent, method for producing the same, and therapeutic agent for hyperkalemia
JP5826445B2 (en) * 2003-02-25 2015-12-02 フィンフィーズ フィンランド オイ Simulated moving floor system and method
WO2005065291A2 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
CA2558029C (en) 2004-03-30 2013-05-07 Ilypsa, Inc. Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
WO2007041569A1 (en) 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties

Also Published As

Publication number Publication date
US8889115B2 (en) 2014-11-18
EP1732524A2 (en) 2006-12-20
EP1732523A1 (en) 2006-12-20
JP2007531726A (en) 2007-11-08
US20160317572A1 (en) 2016-11-03
US10485821B2 (en) 2019-11-26
CA2558029C (en) 2013-05-07
US20080241092A1 (en) 2008-10-02
US8445014B2 (en) 2013-05-21
JP2007531774A (en) 2007-11-08
JP2007531758A (en) 2007-11-08
GB0621242D0 (en) 2006-12-13
US20200085856A1 (en) 2020-03-19
US8216560B2 (en) 2012-07-10
PL1732523T3 (en) 2010-08-31
AU2005231424A1 (en) 2005-10-20
US8778324B2 (en) 2014-07-15
EP1732524A4 (en) 2007-09-19
US20060024265A1 (en) 2006-02-02
KR101228233B1 (en) 2013-01-31
EP1732523B1 (en) 2010-03-17
GB2430367B (en) 2009-08-05
US8287847B2 (en) 2012-10-16
US20110033505A1 (en) 2011-02-10
AU2005231383B2 (en) 2010-06-10
US20090148533A1 (en) 2009-06-11
US20130272990A1 (en) 2013-10-17
BRPI0509366B1 (en) 2018-07-24
US8475780B2 (en) 2013-07-02
EP1732516B1 (en) 2009-12-30
US20080233073A1 (en) 2008-09-25
BRPI0509365B1 (en) 2018-06-12
MXPA06011270A (en) 2007-03-08
WO2005094384A3 (en) 2006-01-26
KR20070007168A (en) 2007-01-12
US20140286891A1 (en) 2014-09-25
WO2005097081A1 (en) 2005-10-20
US8282913B2 (en) 2012-10-09
GB2430368B (en) 2009-08-26
AU2005231424B2 (en) 2010-06-17
AU2005231383A1 (en) 2005-10-20
GB2430368A (en) 2007-03-28
CA2557848A1 (en) 2005-10-20
JP4964122B2 (en) 2012-06-27
EP1732523A4 (en) 2007-06-06
US7776319B2 (en) 2010-08-17
BRPI0509366A (en) 2007-09-04
KR101199608B1 (en) 2012-11-08
GB0621241D0 (en) 2006-12-13
EP1732524B1 (en) 2012-08-22
JP5000480B2 (en) 2012-08-15
DE112005000730B4 (en) 2017-12-21
CA2557848C (en) 2013-12-10
GB2430367A (en) 2007-03-28
EP1732516A1 (en) 2006-12-20
EP1732523B9 (en) 2010-06-02
GB2430624A (en) 2007-04-04
BRPI0509365A (en) 2007-09-04
BRPI0509366B8 (en) 2021-05-25
BRPI0509331A (en) 2007-09-04
KR20060135044A (en) 2006-12-28
US20080241093A1 (en) 2008-10-02
CA2557999A1 (en) 2005-10-13
WO2005097072A1 (en) 2005-10-20
JP4974882B2 (en) 2012-07-11
KR101153035B1 (en) 2012-06-11
GB2430624B (en) 2009-08-05
CA2557999C (en) 2013-11-12
US20130272991A1 (en) 2013-10-17
US20110206631A1 (en) 2011-08-25
KR20060135045A (en) 2006-12-28
US20160082039A1 (en) 2016-03-24
US8409561B2 (en) 2013-04-02
BRPI0509365B8 (en) 2021-05-25
AU2005228696B2 (en) 2010-06-24
BRPI0509331B8 (en) 2021-05-25
EP1732516A4 (en) 2007-06-06
GB0621244D0 (en) 2006-12-13
BRPI0509331B1 (en) 2018-11-27
DE112005000730T5 (en) 2008-07-03
AU2005228696A1 (en) 2005-10-13
WO2005094384A2 (en) 2005-10-13
US20130272992A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
CA2558029A1 (en) Ion binding polymers and uses thereof
JP3996944B2 (en) Anion-binding polymer and its use
CA2762076C (en) Aliphatic amine polymer salts for tableting
US7556799B2 (en) Ion binding polymers and uses thereof
US7854924B2 (en) Methods and compositions for treatment of ion imbalances
JP4499363B2 (en) Method for reducing serum glucose
JP2007530737A (en) Cross-linked amine polymer
CA2626734A1 (en) Magnesium-containing polymers for the treatment of hyperphosphatemia
AU2018206706A1 (en) Ion binding polymers and uses thereof
JP2010519298A (en) Amine polymer composition
US20100316589A1 (en) Coated Pharmaceutical Compositions
WO2023035274A1 (en) Polymer medicament for treating hyperkalemia and preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request